Denali Therapeutics Inc. DNLI
18.89 USD -0.84 (-4.26%)
At closeNov 12, 2026, 4:37 PM EST
18.89 0.00 0.00%
After hours · Nov 12, 4:37 PM ET
18.80 Day range 19.60
15.34 52-week range 27.30
- YTD
- +14.42%
- 1 year
- +7.82%
News
zacks.com DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock? Denali Therapeutics gains 7.8% as Avlayah sales surge nearly fivefold, reimbursement coverage expands and multiple pipeline catalysts approach.
benzinga.com Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42 Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $40 to $42.
benzinga.com Wedbush Maintains Outperform on Denali Therapeutics, Raises Price Target to $24 Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $23 to $24.
benzinga.com BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $39 price target.
seekingalpha.com Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript Denali Therapeutics Inc. (DNLI) Q3 2026 Earnings Call Transcript
marketbeat.com Denali Therapeutics Q3 Earnings Call Highlights Denali Therapeutics NASDAQ: DNLI reported third-quarter 2026 net product revenue of $17.8 million from AVLAYAH, its treatment for Hunter syndrome, as expanding payer coverage and transitions of…
zacks.com Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Beats Revenue Estimates Denali Therapeutics Inc. (DNLI) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $0.74 per share a year ago.- benzinga.com UPDATE: Denali Therapeutics Q3 Adj. EPS $(0.64) Misses $(0.53) Estimate, Sales $17.778M Beat $10.657M Estimate Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.53) by 20.75 percent. This is a 13.51 percent increase over losses…
benzinga.com Denali Therapeutics Q3 2026 Earnings Call Transcript Denali Therapeutics (NASDAQ:DNLI) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Denali Therapeutics Sees Q4 Sales $30.000M-$32.000M vs $22.659M Est Denali Therapeutics (NASDAQ:DNLI) sees Q4 sales of $30.000 million-$32.000 million vs $22.659 million analyst estimate.
benzinga.com Denali Therapeutics Q3 EPS $0.37 Beats $(0.59) Estimate, Sales $17.778M Beat $10.657M Estimate Denali Therapeutics (NASDAQ:DNLI) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $(0.59) by 162.71 percent. This is a 150 percent increase over losses of…
globenewswire.com Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights AVLAYAH® (tividenofusp alfa-eknm) net product revenue accelerated to $17.8 million in its second full commercial quarter Continued growth expectations drive Q4 2026 net product revenue guidance of…
globenewswire.com Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product SOUTH SAN FRANCISCO, Calif., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that AVLAYAH® (tividenofusp alfa-eknm) has been recognized as the “Best…
globenewswire.com Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026 SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that it will report financial results and business highlights for the third…
benzinga.com Denali Therapeutics Q2 2026 Earnings Call Transcript On Thursday, Denali Therapeutics (NASDAQ:DNLI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to…
defenseworld.net Engineers Gate Manager LP Boosts Stock Position in Denali Therapeutics Inc. $DNLI Engineers Gate Manager LP lifted its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 256.5% in the second quarter, according to the company in its most recent disclosure with the Securities…
defenseworld.net WINTON GROUP Ltd Decreases Position in Denali Therapeutics Inc. $DNLI WINTON GROUP Ltd decreased its position in Denali Therapeutics Inc. (NASDAQ: DNLI) by 80.2% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 14,100…
defenseworld.net Critical Survey: Denali Therapeutics (NASDAQ:DNLI) vs. Altimmune (NASDAQ:ALT) Altimmune (NASDAQ: ALT - Get Free Report) and Denali Therapeutics (NASDAQ: DNLI - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses…
seekingalpha.com Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
defenseworld.net BlackRock Inc. Takes Position in Denali Therapeutics Inc. $DNLI BlackRock Inc. bought a new stake in Denali Therapeutics Inc. (NASDAQ: DNLI) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The…
benzinga.com B. Riley Securities Maintains Buy on Denali Therapeutics, Raises Price Target to $35 B. Riley Securities analyst Mayank Mamtani maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $30 to $35.
zacks.com DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock? Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
seekingalpha.com Denali Therapeutics: Bullish On Avlayah And Their Prospects AVLAYAH's approval has helped validate Denali Therapeutics' TransportVehicle platform. They're now moving into their commercial stage as a business. Early payer coverage and Q3 guidance support a…
defenseworld.net Head to Head Comparison: Denali Therapeutics (NASDAQ:DNLI) versus Humacyte (NASDAQ:HUMA) Denali Therapeutics (NASDAQ: DNLI - Get Free Report) and Humacyte (NASDAQ: HUMA - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses…
seekingalpha.com Denali Therapeutics: AVLAYAH Converts A Platform Story Into A Commercial One Denali Therapeutics (DNLI) is transitioning from a neuroscience platform to a commercial biotech with AVLAYAH, its FDA-approved rare-disease therapy. AVLAYAH's Q2 revenue of $3.6M is projected to…
gurufocus.com Baillie Gifford Trims Denali Therapeutics (DNLI) Stake in June Reduction On June 30, 2026, Baillie Gifford (Trades, Portfolio) executed a reduction of 106,249 shares in Denali Therapeutics Inc (NASDAQ: DNLI) at a traded price of $25.7
defenseworld.net Denali Therapeutics Inc. $DNLI Shares Acquired by California State Teachers Retirement System California State Teachers Retirement System increased its position in shares of Denali Therapeutics Inc. (NASDAQ: DNLI) by 25.6% during the first quarter, according to the company in its most recent…
benzinga.com UBS Maintains Buy on Denali Therapeutics, Raises Price Target to $34 UBS analyst Michael Yee maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $25 to $34.
zacks.com DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.
seekingalpha.com Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript Denali Therapeutics Inc. (DNLI) Q2 2026 Earnings Call Transcript- benzinga.com Denali Therapeutics Q2 EPS $(0.68) Misses $(0.65) Estimate, Sales $3.604M Miss $14.613M Estimate Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.65) by 4.62 percent. This is a 5.56 percent increase over losses of…
- benzinga.com Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $36 Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $35 to $36.
- benzinga.com Deutsche Bank Maintains Buy on Denali Therapeutics, Raises Price Target to $35 Deutsche Bank analyst David Hoang maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $31 to $35.
- benzinga.com JP Morgan Reinstates Overweight on Denali Therapeutics, Announces $29 Price Target JP Morgan analyst Jessica Fye reinstates Denali Therapeutics (NASDAQ:DNLI) with a Overweight and announces $29 price target.
- benzinga.com Denali Therapeutics Signs Deal To Sell Its Rare Pediatric Disease Priority Review Voucher For $195M Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195 million.…
- benzinga.com Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35 Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $40 to $35.
- benzinga.com Biogen And Denali Discontinue BIIB122 Development In Idiopathic Parkinson's Disease After Phase 2b LUMA Trial Misses Primary And Secondary Endpoints The Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue…
benzinga.com Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $40 Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $42 to $40.- benzinga.com BTIG Reiterates Buy on Denali Therapeutics, Maintains $39 Price Target BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $39 price target.
- benzinga.com Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $23 Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $25 to $23.
benzinga.com Denali Therapeutics Q1 EPS $(0.69) Beats $(0.71) Estimate Denali Therapeutics (NASDAQ:DNLI) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.71) by 2.82 percent. This is a 11.54 percent increase over losses of…
benzinga.com Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This One Plays Out' Nancy Pelosi Stock Tracker highlighted Claude AI's Denali Therapeutics earnings bet, which targets upside from its rare-disease drug launch.
benzinga.com Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.
benzinga.com Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $34 Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $32 to $34.
benzinga.com Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why Denali shares fall after Takeda exits DNL593 deal; company regains full rights and targets Phase 1/2 data readout by late 2026.- benzinga.com Reported Friday, Denali Therapeutics Regains Full Rights To DNL593 After Takeda Terminates Collaboration, Phase 1/2 FTD-GRN Trial Results Expected By End Of 2026 Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicle™ technologyResults from ongoing Phase 1/2 study in patients with…
- benzinga.com Denali Therapeutics Secures $200M Royalty Funding Following U.S. FDA Accelerated Approval Of Tividenofusp Alfa Item 7.01 Regulation FD Disclosure. Royalty Agreement Closing and Funding On March 27, 2026, the Company received $200.0 million in gross proceeds in connection with the closing of the
- benzinga.com Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42 Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and raises the price target from $40 to $42.
- benzinga.com Goldman Sachs Maintains Buy on Denali Therapeutics, Raises Price Target to $40 Goldman Sachs analyst Salveen Richter maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $35 to $40.
- benzinga.com Stifel Maintains Buy on Denali Therapeutics, Raises Price Target to $41 Stifel analyst Paul Mattels maintains Denali Therapeutics (NASDAQ:DNLI) with a Buy and raises the price target from $34 to $41.